Andrew Moreno

DocwireNews

MB-105, a first-in-class autologous CD5-targeting chimeric antigen receptor (CAR) T-cell therapy, has received orphan drug designation from the FDA for use in relapsed or refractory T-cell lymphoma. March Biosciences, Inc, a clinical stage biotechnology company developing this new CAR T-cell therapy, announced the designation in a press release.&ldquo;Beyond an important regulatory milestone, securing orphan drug designation for MB-105 from the FDA underscores the critical need for new therapeutic options for patients with T-cell lymphoma,&rdquo; remarked March Biosciences co-founder and chief executive officer Sarah Hein, PhD, in the release.This new CAR T-cell therapy is the lead program for March Biosciences and was launched by the company from the Center for Cell and Gene Therapy, Houston, Texas. The ongoing work at the Center on this therapy is a collaboration between Baylor College of Medicine, Houston Methodist Hospital, and Texas Children&rsquo;s Hospital, each located in Houston, Texas.MB-105 is in development for management of CD5-positive T-cell lymphomas, along with CD5-positive T-cell acute lymphoblastic leukemias, chronic lymphocytic leukemias, and mantle cell lymphomas. The therapy features a proprietary CAR design that enables it to preserve certain normal T-cell functions as it targets malignant cells.A phase 1 clinical trial is underway to evaluate MB-105 for relapsed or refractory T-cell lymphoma and T-cell acute lymphoblastic leukemia. The therapy has resulted in a 44% overall response rate for patients with T-cell lymphoma in the trial.&ldquo;The MB-105 Phase 1 trial has shown promising safety and efficacy signals in relapsed / refractory T-cell lymphoma patients. This designation further validates our development strategy as we prepare to initiate our Phase 2 clinical trial in early 2025,&rdquo; Dr. Hein elaborated.ReferenceMarch Biosciences receives FDA orphan drug designation for MB-105, a first-in-class CD5 CAR-T cell therapy, for T-cell lymphoma. Press release. <a href="https://www.globenewswire.com/news-release/2025/01/28/3016342/0/en/March-Biosciences-Receives-FDA-Orphan-Drug-Designation-for-MB-105-a-First-in-Class-CD5-CAR-T-Cell-Therapy-for-T-Cell-Lymphoma.html">GlobeNewswire. January 28, 2025.</a> Accessed January 30, 2025.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

FDA Grants Orphan Drug Designation to CD5-Targeting CAR T-Cell Therapy for T-Cell Lymphoma

Hematology

Use is also being explored for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe